Form 4: ANI Pharmaceuticals Director Shanmugam Muthusamy Sells Shares Under 10b5-1 Plan

Director and Officer of ANI Pharmaceuticals, Muthusamy Shanmugam, executed multiple sales of common stock between May 15 and May 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Muthusamy Shanmugam, a Director and Officer (Head of R&D, COO-Novitium Ops) at ANI Pharmaceuticals, sold shares of common stock between May 15 and May 17, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
• On May 15, 2024, 14,850 shares were sold at a weighted average price of $65.86.
• On May 16, 2024, 16,459 shares were sold at a weighted average price of $63.84.
• On May 17, 2024, 5,836 shares were sold at a weighted average price of $62.09.
• Following these transactions, Shanmugam directly owns 68,652 shares and indirectly owns 745,475 shares through Esjay LLC and 5,000 shares through SS Pharma LLC.
• Shanmugam holds voting and dispositive power over the shares held by both Esjay LLC and SS Pharma LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider selling can sometimes be interpreted negatively by the market, but the existence of a pre-arranged 10b5-1 trading plan often mitigates this concern as it indicates the sales were planned well in advance and not based on current, non-public information.

Stakeholder Impact

• The share sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan may lessen this effect.

Key Dates